Search

ABSTRACTIntroductionNowadays, despite the wide availability of biological drugs and apremilast for psoriasis management, there is always a need for new therapies to customize the therapeutic approach on the basis of the patient’s clinical features and comorbidities, especially in order to achieve a prolonged therapeutic response. Thus, new treatment strategies are required to offer patients a personalized approach. In this scenario, major knowledge on psoriasis pathogenesis led to the development of deucravacitinib, an orally administered selective TYK2 inhibitor.Areas coveredThe aim of this manuscript is to review the current literature on the effectiveness and safety of deucravacitinib in psoriasis to offer readers a wide perspective. The current English literature was analyzed using the PubMed, Google Scholar, Embase, Cochrane Skin, and clinicaltrials.gov databases, selecting the most relevant manuscripts.Expert opinionDeucravacitinib appears to be an innovative weapon for the management of moderate to severe psoriasis. Despite its efficacy and safety profiles have been revealed by RCTs, real-life data are still scant. Certainly, deucravacitinib broadens the range of therapeutic alternatives for psoriasis patients, thus enhancing the holistic and personalized approaches required for the treatment of this disease.

ABSTRACTIntroductionGeneralized pustular psoriasis (GPP) is a rare form of psoriasis (less of 1% of cases). Currently, GPP is recognized as a clinical entity, distinguished from plaque psoriasis. However, there are not guidelines for GPP management and treatments are often derived from plaque psoriasis. Therefore, conventional systemic drugs are usually used as first-line treatment options, and biologics are still used off label. Recently, spesolimab, an anti-IL36 receptor humanized IgG1 monoclonal antibody, has been specifically approved for GPP disease, revolutionizing treatment scenario.Areas coveredThe aim of this review is to investigate current literature on the use of spesolimab for GPP management to underline its potential role in GPP and offer a current clinical perspective. Literature research using the Google Scholar, Pubmed, Embase, Cochrane Skin, and clinicaltrials.gov databases was performed, selecting the most relevant manuscripts.Expert opinionSpesolimab is efficacious and has a consistent and favorable safety profile in patients presenting with a GPP flare. However, despite excellent results in terms of safety and efficacy have been reported by both clinical trials and very limited real-life experiences, long-term data, especially in flare-up prevention, are scant. Thus, while the available data are encouraging, further research is warranted to understand the efficacy, safety, and long-term outcomes associated with spesolimab treatment in GPP.

This paper aims to define the control exerted by geological setting on the evolution and segmentation of the Montaguto earth flow in Southern Italy. A detailed geological survey and multi-temporal maps were used to reconstruct the geological model of La Montagna Mt. and to quantify the evolution of the flow in terms of sediment pulse formation, movement direction and spatial change in earth-flow area. The spatial distribution of structural fabric of the mountainside was compared with (1) planar geometry of earth-flow source area, (2) orientation of strike-slip faults bounding the earth-flow moving core (i.e. movement direction) and (3) kinematic-zone position and extent. We infer that the evolution of the earth flow is controlled by geological structures and lithology. Moreover, the entire basal-slip surface is composed of newly formed basalslip surface in the source area, and corresponds to pre-earth-flow topography downslope from the neck. Implications of our work are that (1) a detailed geological model of an unstable mountainside, combined with information about earth-flow spatial evolution, might be considered as a tool that allows the localization of areas of possible earth-flow enlargement and (2) geological structures constrain earth-flow movement, inducing a predictable seasonal behaviour in terms of movement direction. [ABSTRACT FROM AUTHOR]